Just when pharmaceutical supply chains had begun to recover from the chaos of the pandemic, companies are now faced with the threat of US tariffs and the ongoing investigation into the United States’ reliance on drug imports. Nick Fryer, vice president of marketing, Sheer Logistics discusses.
Pakorn Khantiyaporn Shutterstock